Antithyroid Drug Use During Pregnancy and Risk of Birth Defects in Offspring

Sarfaroj Khan 

Disclosures

April 08, 2021

Takeaway

  • Previously conducted meta-analyses have overestimated the risk of birth defects in offspring associated with antithyroid drug use during pregnancy because of bias.

  • Propylthiouracil (PTU) use during pregnancy is associated with a smaller risk of birth defects vs methimazole/carbimazole (MMI/CMZ) and may be similar in size as that observed with untreated hyperthyroidism.

Why this matters

  • Antithyroid drug use during pregnancy has been associated with an increased risk of birth defects in offspring.

  • However, uncertainty remains on the size of this risk and how it compares to untreated hyperthyroidism because of methodological limitations of previous studies.

Study design

  • 7 cohort studies and 1 case-control study involving 6,212,322 pregnancies and 388,976 birth defects met eligibility criteria after a search on MEDLINE and EMBASE.

  • Funding: None.

Key results

  • Maternal antithyroid drug use during pregnancy was associated with an increased risk of birth defects in offspring compared with unexposed women:

    • PTU (adjusted risk ratio [aRR], 1.16; 95% CI, 1.08-1.25);

    • MMI/CMZ (aRR, 1.28; 95% CI, 1.06-1.54); and

    • exposure to both MMI/CMZ and PTU (aRR, 1.51; 95% CI, 1.16-1.97).

  • The risk of birth defects was significantly higher in unexposed women with hyperthyroidism vs unexposed women without hyperthyroidism (aRR, 1.15; 95% CI, 1.02-1.29).    

  • The risk of any birth defect per 1000 was:

    • 9.6 for unexposed hyperthyroidism;

    • 10.2 for PTU;

    • 17.8 for MMI/CMZ; and

    • 32.5 for both MMI/CMZ and PTU.

  • Corresponding numbers for major birth defects per 1000 live births were 1.2, 1.3, 2.3, and 4.1.

Limitations

  • Risk of residual confounding.

 

Morales DR, Fonkwen L, Nordeng HME. Antithyroid drug use during pregnancy and the risk of birth defects in offspring: systematic review and meta-analysis of observational studies with methodological considerations. Br J Clin Pharmacol. 2021 Mar 30 [Epub ahead of print]. doi: 10.1111/bcp.14805. PMID: 33783857.  View full text 

This clinical summary originally appeared on Univadis, part of the Medscape Professional Network.

Comments

3090D553-9492-4563-8681-AD288FA52ACE
Comments on Medscape are moderated and should be professional in tone and on topic. You must declare any conflicts of interest related to your comments and responses. Please see our Commenting Guide for further information. We reserve the right to remove posts at our sole discretion.
Post as:

processing....